Oncolytics Biotech Announces Publication of Research on Combination Reovirus and Radiation Therapy
News Feb 05, 2008
Oncolytics Biotech Inc. has reported that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work testing combination treatment schedules of reovirus and radiation in human and murine tumor cells in vitro and in vivo.
The paper, entitled "Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy" appears online in the February 1, 2008 issue of Clinical Cancer Research.
The effect of different schedules of reovirus and radiotherapy on viral replication and cytotoxicity was tested in vitro and the combination was assessed in three tumor models in vivo.
The results demonstrated that combining reovirus and radiotherapy significantly increased cancer cell killing both in vitro and in vivo, particularly in cell lines with moderate susceptibility to reovirus alone.
"Dr. Harrington's work demonstrates convincingly that REOLYSIN® works to enhance the effects of radiation therapy," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.
"The results of this preclinical research provided strong support for the combination REOLYSIN® and radiation clinical trials we are conducting in the U.K. To date, we have successfully completed enrolment in a Phase Ia/Ib combination REOLYSIN® and radiation trial and are currently enrolling patients in a Phase II trial using this combination."
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE